{"id":"3ed96d57-7b7e-5a80-b594-6476f5d6b033","stable_key":"4fef8d72-f107-5eb5-b2fb-483ca85465e0:k2-mk7-cad-bone-null","predicate":"did_not_improve","statement":"After three years, BMD declined without significant between-group differences, and microarchitecture and turnover changes were also similar.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"01fa0214-d5b7-5bc7-86f6-8a7015195bd0","mechanism_event_label":"Improved carboxylation did not translate into a demonstrated bone-density benefit in this trial.","subject":{"id":"a3ff2a7b-69f3-5098-8fac-fb8d7668397b","slug":"menaquinone-7","display_name":"Menaquinone-7 / MK-7","entity_type_key":"small_molecule"},"object":{"id":"8967827f-50c6-55f2-9c8a-dfc05fd70a77","slug":"bone-mineral-density","display_name":"Bone mineral density","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"01fa0214-d5b7-5bc7-86f6-8a7015195bd0","stable_key":"4fef8d72-f107-5eb5-b2fb-483ca85465e0:k2-mk7-cad-bone-null-event","event_type":"observed_intervention","label":"Improved carboxylation did not translate into a demonstrated bone-density benefit in this trial.","description":"After three years, BMD declined without significant between-group differences, and microarchitecture and turnover changes were also similar.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"b162e431-b442-5400-9335-ec91f7875a4e","slug":"cholecalciferol","display_name":"Cholecalciferol","entity_type_key":"small_molecule"},"role":"shared_background","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"8e2a5a1f-cd49-5f28-8611-325266fb78a6","slug":"calcium","display_name":"Calcium","entity_type_key":"nutrient_element"},"role":"shared_background","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"1cecdab6-83c8-5cab-aafa-c246354ad52b","slug":"bone-microarchitecture","display_name":"Bone microarchitecture","entity_type_key":"cellular_process"},"role":"other_null_readout","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"a3ff2a7b-69f3-5098-8fac-fb8d7668397b","slug":"menaquinone-7","display_name":"Menaquinone-7 / MK-7","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"8967827f-50c6-55f2-9c8a-dfc05fd70a77","slug":"bone-mineral-density","display_name":"Bone mineral density","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/k2-research/33030563.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"008ef1b176a3f718d923eea696a7a97b09d64e3079e57c997beaf485153ca138\", \"start_char\": 0, \"end_char\": 2370, \"text_sha256\": \"008ef1b176a3f718d923eea696a7a97b09d64e3079e57c997beaf485153ca138\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Three-year double-blind randomized add-on trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"MK-7 375 micrograms/day versus placebo; both groups D3 38 micrograms/day and calcium 800 mg/day","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Different population, dose and background supplementation from the 180-microgram trial; the one-year and three-year reports are not independent cohorts.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"k2","display_name":"Vitamin K2 / menaquinone family","entity_type_key":"chemical_species"}},{"dimension":"organism","value_text":"142 postmenopausal women with osteopenia","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"Improved carboxylation did not translate into a demonstrated bone-density benefit in this trial.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[k2-p33030563] The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33030563/ DOI: 10.1007/s00198-020-05638-z","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Osteocalcin, DXA and bone microarchitecture","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"57cc330d-5cff-5d52-bbf0-16add027e5e1","evidence_kind":"source_excerpt","locator":"Lines 1098-1109","start_line":1098,"end_line":1109,"excerpt":"### k2-mk7-cad-bone-null\nAfter three years, BMD declined without significant between-group differences, and microarchitecture and turnover changes were also similar.\nCondition category: normal\nnutrient_topic: Vitamin K2 research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: Improved carboxylation did not translate into a demonstrated bone-density benefit in this trial.\norganism: 142 postmenopausal women with osteopenia\ntissue_or_cell_type: Osteocalcin, DXA and bone microarchitecture\nexperimental_model: Three-year double-blind randomized add-on trial\nlimitations: Different population, dose and background supplementation from the 180-microgram trial; the one-year and three-year reports are not independent cohorts.\nexposure: MK-7 375 micrograms/day versus placebo; both groups D3 38 micrograms/day and calcium 800 mg/day\nevidence_span: {\"source_cache\": \"artifacts/k2-research/33030563.abstract.txt\", \"locator\": \"Exact primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"008ef1b176a3f718d923eea696a7a97b09d64e3079e57c997beaf485153ca138\", \"start_char\": 0, \"end_char\": 2370, \"text_sha256\": \"008ef1b176a3f718d923eea696a7a97b09d64e3079e57c997beaf485153ca138\"}\n[k2-p33030563] The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33030563/ DOI: 10.1007/s00198-020-05638-z","model_system":"Three-year double-blind randomized add-on trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [k2-p33030563] The effect of vitamin MK-7 on bone mineral density and microarchitecture in postmenopausal women with osteopenia, a 3-year randomized, placebo-controlled clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33030563/ DOI: 10.1007/s00198-020-05638-z","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"dfeae572-af3d-5042-a10e-e67596f9ab28","stable_key":"import-4fef8d72-f107-5eb5-b2fb-483ca85465e0","title":"Vitamin K2: menaquinone forms, carboxylation, recycling and nutrient interactions (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"dc31aff21110d09b025c177e03b4c5ca8349d52bf5f962285fdbfcf660c0e4f6","revision_id":"850887db-34f6-55aa-9d3e-b8fd3a4a5de3","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}